Archive · 14 Sep 2025
PharmEasy Struggles: Debt, Losses, and Founder Exit
PharmEasy, a company that lets people buy medicine online, is in a bit of trouble.
They spent a lot of money to buy another company, Thyrocare, but it didn't make them more profitable.
They borrowed a lot of money which they now have to pay back with high interest.
They lost a lot of money last year and have become worth a lot less.
The original boss stepped down.
Now, they are trying to figure out how to make the company successful again.
They are now focusing on selling medicine to other businesses, but still losing money.
PharmEasy acquired Thyrocare in 2021 with the hope of increasing profitability, but the company has still not achieved this goal.
The company reported a loss of INR 1,517 Cr in FY25, although this was an improvement over the previous year's loss.
PharmEasy took on a $300 million loan with a high interest rate, adding to its financial strain.
Founder Siddharth Shah stepped down as CEO in August 2025.
The company's valuation has significantly decreased.
- Who
- PharmEasy, an Indian online pharmacy and healthcare platform.
- What
- PharmEasy is facing financial difficulties including high debt, losses, and a decline in valuation after acquiring Thyrocare.
- When
- The issues have developed over the past few years, particularly after a large loan was taken in 2022, and amid a decline in the Indian startup ecosystem.
- Where
- India.
- Why
- The company's troubles are due to a high debt burden, failure to raise sufficient capital, and a shift in focus to B2B sales.
- Company
- PharmEasy
- Key Acquisition
- Thyrocare (2021)
- FY25 Loss
- INR 1,517 Cr
- 2022 Debt (Goldman Sachs)
- $300 Mn (INR 2,220 Cr) at 17-18% interest
- Founder Exit
- Siddharth Shah stepped down as CEO in August 2025
- Current Valuation
- $500-600 Mn (estimated)